-
公开(公告)号：US20180296614A1
公开(公告)日：2018-10-18
申请号：US15768147
申请日：2016-10-14
申请人： Duke University
IPC分类号： A61K35/768 , A61K39/13 , A61K9/127 , A61K39/395 , C07K16/28 , A61P35/00 , C12N15/85
CPC分类号： A61K35/768 , A61K9/127 , A61K39/13 , A61K39/39 , A61K39/39541 , A61K2039/505 , A61K2300/00 , A61P35/00 , C07K16/2818 , C07K2317/76 , C12N7/00 , C12N15/85 , C12N2770/32621 , C12N2770/32632 , C12N2840/203 , Y02A50/466
摘要： Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
-
2.发明申请公开(公告)号：US20180273631A1
公开(公告)日：2018-09-27
申请号：US15934334
申请日：2018-03-23
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2875 , C07K2317/21 , C07K2317/24 , C07K2317/74 , C07K2317/75 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/466
摘要： Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
-
公开(公告)号：US20180251498A1
公开(公告)日：2018-09-06
申请号：US15329870
申请日：2015-07-29
发明人： Vadim METT
IPC分类号： C07K14/195 , A61K38/16 , A61K45/06
CPC分类号： C07K14/195 , A61K38/164 , A61K39/0013 , A61K39/02 , A61K39/39 , A61K45/06 , A61K2039/55505 , A61K2039/55516 , A61K2039/55583 , A61K2039/55594 , A61K2039/57 , A61K2039/575 , C07K2319/00 , C07K2319/21 , Y02A50/388 , Y02A50/39 , Y02A50/466 , Y02A50/484
摘要： The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.
-
4.发明申请公开(公告)号：US20180215823A1
公开(公告)日：2018-08-02
申请号：US15934447
申请日：2018-03-23
CPC分类号： C07K16/2809 , A61K2039/505 , C07K16/2887 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/734 , C07K2317/74 , C07K2317/92 , Y02A50/386 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/412 , Y02A50/466 , Y02A50/487 , Y02A50/489
摘要： The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
-
公开(公告)号：US20180162933A1
公开(公告)日：2018-06-14
申请号：US15832177
申请日：2017-12-05
发明人： Bernhard K. Mueller , Martin Schmidt , Eve Barlow , Mary Leddy , Chung-Ming Hsieh , Philip Bardwell
IPC分类号： C07K16/22 , A61K45/06 , A61K39/395 , A61K39/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , Y02A50/466
摘要： The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
-
6.发明申请公开(公告)号：US20180133311A1
公开(公告)日：2018-05-17
申请号：US15843177
申请日：2017-12-15
IPC分类号： A61K39/39 , A61K39/00 , A61K38/17 , C12N5/0784
CPC分类号： A61K39/39 , A61K38/177 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/53 , A61K2039/54 , C12N5/0639 , C12N2510/00 , Y02A50/386 , Y02A50/388 , Y02A50/394 , Y02A50/397 , Y02A50/40 , Y02A50/401 , Y02A50/403 , Y02A50/407 , Y02A50/41 , Y02A50/466 , Y02A50/467 , Y02A50/469 , Y02A50/478 , Y02A50/48 , Y02A50/484
摘要： We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TILR4 (caTLR4).
-
公开(公告)号：US20180126001A1
公开(公告)日：2018-05-10
申请号：US15620679
申请日：2017-06-12
发明人： Marek Malecki , Roman Malecki
CPC分类号： A61K47/6851 , A61K33/00 , A61K39/12 , A61K39/292 , A61K47/6811 , A61K47/6855 , A61K47/6923 , A61K49/0002 , A61K49/16 , A61K51/1241 , A61K2039/505 , A61K2039/5258 , A61K2039/55505 , A61K2039/55555 , A61K2039/585 , A61K2039/6056 , A61K2039/627 , A61K2039/64 , C07K16/082 , C07K16/30 , C07K16/32 , C07K2317/54 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/94 , C12N2730/10123 , C12N2730/10134 , C12N2730/10171 , Y02A50/383 , Y02A50/386 , Y02A50/388 , Y02A50/392 , Y02A50/466
摘要： Hereby, we disclose and claim, the concept, designs, enabling technologies, and utility for therapy of patients suffering from cancer, of a novel class of biomolecularly engineered, synthetic molecules: antibody-vaccine engineered constructs (AVEC). They comprise the main functional domains (antibodies and vaccines) and the supporting domains (linkers and reporters). Their mechanisms of actions rely upon antibody dependent redirecting, accelerating, and amplifying of the prophylactic or natural vaccination induced immune response (ADRAAVIR) from the initially elicited by vaccination towards the finally aimed by therapies. The routes of administration to the patients, pharmacokinetics, pharmacodynamics, pharmacogenomics, and therapeutic efficacies are resultant of those of the pertinent antibodies and vaccines assembled within AVEC.
-
公开(公告)号：US20180117144A1
公开(公告)日：2018-05-03
申请号：US15565752
申请日：2016-04-11
IPC分类号： A61K39/385
CPC分类号： A61K39/385 , A61K9/0019 , A61K2039/572 , A61K2039/6037 , A61K2039/6056 , Y02A50/388 , Y02A50/466 , Y02A50/484
摘要： The invention relates to engineered anthrax toxin compositions that can target antigen-presenting cells such as dendritic cells. Specifically, the compositions comprise (a) a native-receptor-ablated anthrax toxin protective antigen (PA) fused to a receptor-binding moiety specific for a target receptor on a dendritic cell and (b) a lethal factor (LF) or a fragment thereof fused to an active moiety comprising at least one repeat of a disease-specific antigen. The invention also relates to methods of using these compositions for targeted delivery to dendritic cells, methods of enhancing CTL activation, and methods of inducing an immune response to cancers, bacteria, and/or viruses.
-
公开(公告)号：US20180104324A1
公开(公告)日：2018-04-19
申请号：US15819312
申请日：2017-11-21
IPC分类号： A61K39/09 , A61K39/13 , A61K9/00 , A61K39/00 , A61K39/05 , A61K39/08 , A61K39/02 , C12N7/00 , A61K39/12
CPC分类号： A61K39/092 , A61K9/0019 , A61K39/0018 , A61K39/05 , A61K39/08 , A61K39/099 , A61K39/12 , A61K39/13 , A61K47/646 , A61K2039/55 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , C12N7/00 , C12N2770/32334 , C12N2770/32634 , Y02A50/466
摘要： Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.
-
10.发明申请公开(公告)号：US20180099039A1
公开(公告)日：2018-04-12
申请号：US15286696
申请日：2016-10-06
申请人： Pfizer Inc.
发明人： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC分类号： A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/466
摘要： The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
-
-
-
-
-
-
-
-
搜索结果
1590 条记录 (耗时 0.044 秒)
